Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

Update your browser to view ScienceDirect correctly.

Your technical details and browser version:

Request ID: 95a02d749983fa1a-LAX IP: 47.97.18.252 UTC time: 2025-07-04T17:00:13+00:00 Browser: Mozilla/5.0 (X11; U; Linux x86_64; en-US; rv:1.9.1.4) Gecko/20091030 Gentoo Firefox/3.5.4

View original article

GYNECOLOGIC ONCOLOGY

Like

Share Bookmark

0 0 0 0 0 0 0

More from this channel

Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma

Comments (0)